4.29
+8.06%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Collplant Biotechnologies
Its shares trade under the ticker CLGN. It has been listed since 1 September 1993. In the fiscal year to 31 December 2025, it reported revenue of $2.4m and a net loss of $11.5m. At that date it held total assets of $10.8m and shareholders' equity of $6.1m.
CollPlant Biotechnologies Ltd. is a regenerative medicine company, which engages in the research, development, manufacture, and marketing of medical products for tissue repair such as bioprinting of tissues and organs, and medical aesthetics. The firm provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 1 Sept 1993
- Employees
- 38
- Website
- collplant.com ↗
- Head office
- 4 OPPENHEIMER ST., 11TH FLOOR, REHOVOT, L3, 74140
- Incorporated in
- L3
- Classification
- Orthopedic, Prosthetic & Surgical Appliances & Supplies
- Filer status
- Non-accelerated filer
Leadership
Pay as last reported
- Dr. Roger PomerantzIndependent Chairman of the Board
- Mr. Yehiel TalChief Executive Officer$761,000
- Mr. Eran RotemDeputy Chief Executive Officer, Chief Financial Officer$625,000
- Dr. Ilana BelzerChief Operating Officer$352,000
- Mrs. Hadas Dreiher HorowitzVice President - Human Resources
- Mr. Bowman BagleyVice President - Commercial North America
- Dr. Philippe BensimonVice President - Regulatory Affairs and Quality Assurance$308,000
- Dr. Nadav OrrVice President - Research & Development$350,000
- Dr. Oded ShoseyovFounder, Chief Scientist, since 2008ILS 946,000
- Dr. Gili HartIndependent Director
- Dr. Abraham HavronIndependent Director
- Ms. Alisa LaskIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- CollPlant Biotechnologies Ltd. develops plant-based collagen for tissue repair and bioprinting applications.
- The company's rhCollagen technology enables regenerative medicine solutions for organ production.
- With 38 employees, CollPlant focuses on specialized biotechnology research in Rehovot, Israel.
Weaknesses
- CollPlant's business is limited to regenerative medicine and tissue repair applications.
- The company operates with a small team of 38 employees in the biotechnology sector.
- CollPlant's focus on plant-based collagen restricts its market scope to specific medical fields.
Opportunities
- CollPlant can expand its bioprinting technology into medical aesthetics markets.
- Growing demand for regenerative medicine solutions in the Health Care sector presents opportunities.
- CollPlant's rhCollagen technology may attract partnerships in the biotechnology industry.
Threats
- CollPlant faces competition from other biotechnology firms in the Health Care sector.
- Regulatory challenges in medical product development could delay market entry.
- The small employee count of 38 may limit CollPlant's capacity for rapid innovation.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.